All entries for: ReCode Therapeutics

ReCode Therapeutics raised $31 million to advance its pipeline of therapies, including RCT1100, an inhaled mRNA treatment for Primary Ciliary Dyskinesia (PCD), a rare genetic disorder that causes chronic respiratory infections and progressive lung function decline.

ReCode Therapeutics raised undisclosed funding to develop lipid nanoparticle platforms for precise delivery of genetic therapies to specific organs and tissues, offering new options for patients with life-limiting rare diseases.